

Generic Name: Weight Loss Agents

Therapeutic Class or Brand Name: Weight Loss Agents

Applicable Drugs: Adipex-P, benzphetamine, Contrave® ER (naltrexone/bupropion), diethylpropion, diethylpropion ER, phendimetrazine, phendimetrazine ER, phentermine, Lomaira™, orlistat, Qsymia® (phentermine/topiramate extended-release), Saxenda® (liraglutide), Wegovy™ (semaglutide), Xenical®

Preferred: Please refer to the Plan Document for Preferred Products

Non-preferred: Please refer to the Plan Document for Non-preferred Products

Date of Origin: 12/12/2022

Date Last Reviewed / Revised: 12/12/2022

PRIOR AUTHORIZATION CRITERIA

(May be considered medically necessary when criteria I to V are met)

- I. Treatment is being requested for weight management, and criterion A or B is met
 - A. Patient is at least 18 years of age and meets criteria i or ii below:
 - i. The patient's baseline weight and documented body mass index (BMI) is 30 kg/m² or greater (obese).
 - ii. The patient's baseline weight, documented BMI of 27 kg/m² or greater (overweight) AND has at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).
 - B. Patient is 12 to less than 18 years of age and meets criteria i and ii below:
 - i. Documented body weight above 60 kg.
 - ii. Initial BMI corresponding to 30 kg/m² in adults by international cutoffs (see Appendix Table 1).
- II. Documented trial of reduced-calorie diet (approximately 500 kcal/day deficit) and exercise plan (recommended increase in physical activity of a minimum 150 minutes per week) for at least 3 months.
- III. The requested medication will be used as an adjunct to a reduced-calorie diet and exercise plan.
- IV. The patient meets specific age criteria in accordance with FDA labeling (see Age / Quantity / Days Supply Restrictions).
- V. Refer to the plan document for the list of preferred products. If the request is for a brand medication for which a generic is available, there must be a documented treatment failure or contraindication to the generic medication.

EXCLUSION CRITERIA

- Pregnancy
- Concurrent use with other products for weight loss.
- For GLP-1 receptor agonists, the following exclusions apply:
 - Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
 - Concurrent use with any other GLP-1 receptor agonists or insulin.
 - History of pancreatitis.
 - Treatment of type 2 diabetes.

OTHER CRITERIA

- Weight management medications must be a covered benefit.

AGE / QUANTITY / DAYS SUPPLY RESTRICTIONS*

- Contrave® ER: 18 years and older. Up to 120 tablets per 30 days
- Phentermine Products:
 - Lomaira®: Age ≥17 years, Up to 90 tablets per 30 days.
 - Adipex-P and all others: Age ≥17 years, 30 tablets or capsules per 30 days
- Saxenda®: Age ≥12 years, 5 pens (15 mL) per 30 days.
- Wegovy: Age ≥12 years, 4 pens (3 mL) per 28 days.
- Orlistat products:
 - Xenical: Age ≥12 years, 90 capsules per 30 days.
 - Alli: Age ≥18 years, 90 capsules per 30 days.

*Exceptions to these quantity limits for dose titration/de-escalation will be reviewed on a case-by-case basis.

APPROVAL LENGTH

- **Authorization:**
 - Wegovy: 28 weeks
 - All other agents: 16 weeks
- **Re-Authorization:** 28 weeks. An updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective. Documentation that criterion 1 TO 3 are met:

1. Patient is tolerating the medication.
 - Wegovy maintenance dose of 2.4 mg once weekly
2. Patient has lost at least 4% of baseline body weight (weight-loss medications should be discontinued if the patient has not lost at least 4% of baseline body weight, since it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment).
3. The patient continues to be on reduced-calorie diet (approximately 500 kcal/day deficit) and exercise plan (recommended increase in physical activity of minimum 150 minutes per week).

APPENDIX

Table 1. International Obesity Task Force BMI Cut-Offs for Obesity by Sex and Age For Pediatric Patients Aged 12 years and Older (Cole Criteria)

Age (years)	Body mass index 30 kg/m ²	
	Males	Females
12	26.02	26.67
12.5	26.43	27.24
13	26.84	27.76
13.5	27.25	28.20
14	27.63	28.57
14.5	27.98	28.87
15	28.30	29.11
15.5	28.60	29.29
16	28.88	29.43
16.5	29.14	29.56
17	29.41	29.69
17.5	29.70	29.84

REFERENCES

1. Contrave. Prescribing information. Currax Pharmaceuticals LLC; 2021. Accessed November 11, 2022. https://contrave.com/wp-content/uploads/2022/02/Contrave_PI_CON-LC115.02_0222.pdf
2. Phentermine capsules. Prescribing information. Sandoz; 2017. Accessed November 11, 2022. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c6651a6-b588-4873-9f13-41b7af1c3d58>
3. Lomaira. Prescribing information. KVK-Tech; 2016. Accessed November 11, 2022. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cde9fb09-e5af-434d-8874-e4f9f974d893>.
4. Qsymia. Prescribing information. VIVUS LLC; 2022. Accessed November 11, 2022. <https://qsymia.com/patient/include/media/pdf/prescribing-information.pdf?v=0422>
5. Saxenda. Prescribing information. Novo Nordisk Inc.; 2022. Accessed November 11, 2022. <http://www.novo-pi.com/saxenda.pdf>.
6. Wegovy. Prescribing information. Novo Nordisk Inc; 2022. Accessed December 12, 2022. <https://www.novo-pi.com/wegovy.pdf>.
7. Alli. Prescribing information. GlaxoSmithKline; 2014. Accessed November 11, 2022. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2d3bd73-f3af-4ea5-a57c-66b0004cfe4f>.
8. Xenical. Prescribing information. H2-Pharma LLC; 2018. Accessed November 11, 2022. https://xenical.com/pdf/PI_Xenical-brand_FINAL.PDF.
9. Apovian C, Aronne L, Bessesen D, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2015;100(2):342-362. Accessed September 8, 2022. doi:10.1210/jc.2014-3415.

DISCLAIMER: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgement in providing the most appropriate care for their patients.